Co-Founder, Ceo
CurrentThe “Holy Grail” in cancer is to kill cancer cells, but not kill healthy cells. Pharma companies have historically searched for natural biomarkers on cancer cells to therapeutically target them. Earli turns that approach on its head. Instead of searching for natural targets, Earli creates programmable genetic constructs that enter cancer cells and force them to reveal, and ultimately kill themselves.The genetic constructs switch on only in cancer cells and force them to become “factories” that produce any signal protein of choice, encoded in the genetic sequence. The proteins are used for imaging (diagnostic) or for activating the immune system against the cancer (therapeutic). Earli is based in Redwood City, CA, and has raised $92M from Andreessen Horowitz (a16z)'s Bio Fund, Khosla Ventures, life science hedge funds Perceptive Advisors and Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, etc. https://earli.com.